Research programme: oculopharyngeal muscular dystrophy therapeutics - Benitec/Institut de Myologie/Royal Holloway University of London

Drug Profile

Research programme: oculopharyngeal muscular dystrophy therapeutics - Benitec/Institut de Myologie/Royal Holloway University of London

Alternative Names: BB-301; Pabparna™

Latest Information Update: 19 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Benitec Ltd; University of London
  • Developer Benitec Biopharma
  • Class Small interfering RNA
  • Mechanism of Action Gene silencing; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oculopharyngeal muscular dystrophy
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Oculopharyngeal muscular dystrophy

Most Recent Events

  • 17 Jan 2017 BB 301 receives Orphan Drug status for Oculopharyngeal muscular dystrophy in European Union
  • 17 Jan 2017 Benitec Biopharma plans a phase I/II trial for in Oculopharyngeal muscular dystrophy in second half of 2018
  • 25 Apr 2016 Pharmacodynamics data from a preclinical trial in Oculopharyngeal muscular dystrophy released by Benitec
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top